Kidney Function and Glycemic Control in Pretransplant versus Post-Transplant Diabetes: A Long-Term Study of Predominantly Non-Kidney Solid-Organ Transplant Recipients
This long-term study of solid-organ transplant recipients with diabetes reveals that while pretransplant diabetes is associated with lower kidney function, this difference is not independent of other factors, and the cohort exhibits substantial kidney dysfunction and suboptimal glycemic control with limited use of cardiorenal-protective therapies like SGLT2 inhibitors.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When a person receives a new liver, heart, or kidney, the body's immune system must be gently persuaded to accept this foreign organ. To prevent rejection, doctors prescribe powerful medicines that calm the immune response. However, these same medicines can sometimes cause the pancreas to struggle with insulin or make the body resistant to it, leading to high blood sugar. This condition, known as diabetes, can develop before the transplant or appear afterward. For years, doctors have worried that this high blood sugar, combined with the long-term effects of the anti-rejection drugs, might silently damage the kidneys. While the kidneys are the primary filter for the blood, they are not just passive victims; they are also the organs that determine how well a patient can survive and thrive decades after the surgery. Understanding how these two forces—diabetes and the necessary medicines—interact over time is crucial for keeping transplant recipients healthy.
A team of researchers in Brazil set out to examine this long-term relationship by looking at the medical records of 113 adults who had received solid-organ transplants and were living with diabetes. These patients had undergone surgery an average of nearly eleven years prior, with the majority receiving a liver, followed by kidney and heart transplants. The researchers wanted to see if there was a difference in how the kidneys fared and how well blood sugar was controlled between those who had diabetes before their surgery and those who developed it only after. They also looked at whether the timing of the diabetes onset mattered and how often patients were using a newer class of drugs designed to protect both the heart and kidneys.
The study revealed that the group of patients who had diabetes before their transplant was generally older and had been living with the condition for a longer time than those who developed it later. When the researchers first compared the two groups, the patients with pre-existing diabetes appeared to have lower kidney function. However, once the researchers adjusted for the fact that these patients were older and had spent less time since their surgery, the difference in kidney function disappeared. This suggests that the lower kidney performance was not caused by the diabetes classification itself, but rather by the age of the patients and the specific organ they had received. In fact, the patients who developed diabetes after the transplant had actually been living with their new organ for a longer period, averaging over thirteen years, compared to just under seven years for the pre-existing group.
Despite these adjustments, the overall picture for the entire group was one of significant strain. The average blood sugar control was slightly above the target level recommended for most adults, and nearly half of the patients had some degree of kidney dysfunction. A particularly striking finding was that kidney damage did not always follow the traditional pattern seen in standard diabetes. Usually, when kidneys begin to fail due to diabetes, they start leaking a protein called albumin into the urine, which serves as an early warning sign. In this group of transplant recipients, however, the researchers found that many patients had reduced kidney function without any albumin leakage, while others had albumin leakage despite having normal filtration rates. This disconnect indicates that the damage in these patients is likely driven by different factors, such as the long-term effects of anti-rejection drugs or high blood pressure, rather than the classic diabetic pathway.
The researchers also discovered that a specific type of medication, known as an SGLT2 inhibitor, which is known to protect the heart and kidneys, was being used far less often than it should be. Even among the patients who had clear signs of kidney stress or albumin in their urine, only about two out of five were taking this protective medication. The study suggests that doctors may be hesitant to prescribe these newer drugs to transplant patients due to a lack of specific long-term data, even though the patients in this study who did take them were generally older and had more advanced kidney issues, indicating they were the ones who needed the protection most.
Ultimately, this long-term look at transplant recipients paints a picture of a complex medical landscape where the benefits of a new organ are constantly balanced against the side effects of the medicines required to keep it. The findings indicate that kidney problems in these patients are common and often do not show the classic warning signs of diabetes, making them harder to detect. Furthermore, the study highlights a gap in care, where many high-risk patients are not receiving the modern therapies that could help preserve their kidney function. The researchers conclude that while the timing of when diabetes appears does not seem to change the long-term outlook for kidney health, there is an urgent need for better monitoring and more systematic use of kidney-protective treatments to ensure these patients continue to live healthy lives decades after their surgery.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.